European Research Council grant · Finished
MeTIC Methyltransferase inhibitors for treatment of COVID19
- Coordinator
- Technische Universitaet Muenchen, Germany
- Runs
- 1 June 2022 to 30 November 2023
- Status
- Finished
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101069369
What the project is doing
In the project's own words, from its summary on CORDIS.
Our IP secured drug DZNep is effective in treating SARS-CoV-2 infections in preclinical disease models and uniquely suppresses virus growth, triggers the innate immunity and facilitates tissue regeneration. The ERC-PoC will enable the transition from preclinical to clinical research.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Technische Universitaet Muenchen | Muenchen | Germany | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI